This podcast series was initiated and fully funded by Sanofi. The content has been reviewed and approved by the sponsoring company and speakers prior to broadcast. Editorial support for this podcast was provided by OmniaMed Communications. GPnotebook has had no input into the content of this podcast series. © 2022 Sanofi
The InRange study is the first randomised controlled trial to use Time in Range as a primary endpoint to compare the second-generation basal insulin analogues Toujeo® (insulin glargine 300 U/mL) and insulin degludec 100 U/mL in people with type 1 diabetes.¹ To access further information, please visit the promotional Sanofi Diabetes website https://www.sanofidiabetes.co.uk/en/products/toujeo/evidence/in-range.
Battelino T et al. Diabetes Ther 2020;11:1017–1027.
Adverse events should be reported.
Great Britain and Northern Ireland reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Sanofi Tel: 0800 090 2314. Alternatively, send via email to [email protected].
Republic of Ireland reporting forms and information can be found at www.hpra.ie; email: [email protected]. Adverse events should also be reported to Sanofi Ireland Ltd. Tel: 01 403 5600. Alternatively, send via email to [email protected].
This podcast episode is intended for healthcare professionals based in Great Britain, Northern Ireland and the Republic of Ireland
Would you like to receive updates about new podcast episodes by email? (You can unsubscribe at any time)